Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside

Nature Reviews Rheumatology volume 5, pages 139–148 (2009)Cite this article

Abstract

One of the strongest clinical associations with autoantibodies against components of the SSA/Ro–SSB/La ribonucleoprotein complex is the development of congenital heart block in an offspring, an alarming prospect facing 2% of primigravid mothers with these reactivities. This risk is increased tenfold in women who have had a previous child with congenital heart block. Accumulated evidence suggests that anti-SSA/Ro and anti-SSB/La antibodies are necessary but insufficient for fetal disease. Basic and clinical research is heavily focused on identifying fetal and environmental factors that convert disease susceptibility to disease development. A disturbing observation that has emerged from current research efforts is the rapidity of disease progression, with advanced heart block and life-threatening cardiomyopathy being observed less than 2 weeks after detection of a normal sinus rhythm. Once third-degree block is unequivocally identified, reversal has never been achieved, despite dexamethasone treatment. Accordingly, strategies aimed at preventing disease before irrevocable scarring ensues assume a high priority. One approach has been the implementation of serial echocardiography to monitor for a prolonged PR interval. Intravenous immunoglobulin is being evaluated as a potential prophylactic approach in mothers who have previously had an affected child.

Key Points

  • Mothers with anti-SSA/Ro antibodies face a 2% risk of having a child with congenital heart block if it is a first pregnancy or if previous babies have all been healthy

  • A previous child with congenital heart block raises the risk of having another by almost tenfold

  • Normal sinus rhythm can progress to complete block in 7 days; thus, frequent monitoring of a pregnancy in a mother with anti-SSA/Ro antibodies is appropriate

  • A mechanical PR interval of greater than 150 ms is consistent with first-degree block, and warrants an immediate discussion regarding the use of a fluorinated steroid to potentially reverse the situation

  • Intravenous immunoglobulin is currently being evaluated as a prophylactic therapy

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The pathogenesis of congenital heart block: current working hypothesis.
Figure 2: Translational approach for managing and preventing congenital heart block.

Similar content being viewed by others

References

  1. Buyon JP et al. (1996) The effects of pregnancy on autoimmune diseases. Clin Immunol Immunopath 78: 99–104

    Article  CAS  Google Scholar 

  2. Buyon JP and Clancy RM (2006) Neonatal lupus. In Dubois' Lupus Erythematosus, edn 7, 1058–1080 (Eds Wallace DJ and Hahn BH) Philadelphia: Lippincott Williams & Wilkins

    Google Scholar 

  3. Leach JL et al. (1996) Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol 157: 3317–3322

    CAS  PubMed  Google Scholar 

  4. Jaeggi ET et al. (2002) Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. J Am Coll Cardiol 39: 130–137

    Article  PubMed  Google Scholar 

  5. Moak JP et al. (2001) Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 37: 238–242

    Article  CAS  PubMed  Google Scholar 

  6. Buyon JP et al. (1998) Autoimmune-associated congenital heart block: mortality, morbidity, and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 31: 1658–1666

    Article  CAS  PubMed  Google Scholar 

  7. Waltuck J and Buyon J (1994) Autoantibody-associated congenital heart block: outcome in mothers and children. Annals Int Med 120: 544–551

    Article  CAS  Google Scholar 

  8. Brucato A et al. (2001) Risk of congenital heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis. Arthritis Rheum 44: 1832–1835

    Article  CAS  PubMed  Google Scholar 

  9. Friedman DM et al. (2008) Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 117: 485–493

    Article  PubMed  Google Scholar 

  10. Salomonsson S et al. (2002) A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 46: 1233–1241

    Article  CAS  PubMed  Google Scholar 

  11. Salomonsson S et al. (2005) Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 201: 11–17

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Buyon JP et al. (1994) Autoantibody responses to the “native” 52 kDa SS-A/Ro protein in neonatal lupus syndromes, systemic lupus erythematosus and Sjögren's syndrome. J Immunology 152: 75–84

    Google Scholar 

  13. Clancy RM et al. (2005) Maternal antibody responses to the 52 kDa SSA/Ro p200 peptide and the development of fetal conduction defects. Arthritis Rheum 52: 3079–3086

    Article  CAS  PubMed  Google Scholar 

  14. Solomon DG et al. (2003) Birth order, gender and recurrence rate in autoantibody-associated congenital heart block: implications for pathogenesis and family counseling. Lupus 12: 646–647

    Article  PubMed  Google Scholar 

  15. Gordon P et al. (2004) Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheum 31: 2480–2487

    CAS  PubMed  Google Scholar 

  16. Vincent A et al. (2000) Molecular targets for autoimmune and genetic disorders of neuromuscular transmission. Eur J Biochem 267: 6717–6728

    Article  CAS  PubMed  Google Scholar 

  17. Kreier JP (2002) Infection, Resistance and Immunity, edn 2. Oxford, UK: Taylor & Francis

    Google Scholar 

  18. Alexander E et al. (1992) Anti-Ro/SS-A antibodies in the pathophysiology of congenital heart block in neonatal lupus syndrome, an experimental model: in vitro electrophysiologic and immunocytochemical studies. Arthritis Rheum 35: 176–189

    Article  CAS  PubMed  Google Scholar 

  19. Garcia S et al. (1994) Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. J Clin Invest 93: 718–724

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Boutjdir M et al. (1998) Serum and IgG from the mother of a child with congenital heart block induce conduction abnormalities and inhibit L-type calcium channels in a rat heart model. Pediatr Res 80: 354–362

    Google Scholar 

  21. Buyon JP et al. (2002) Cardiac 5-HT4 serotoninergic receptors, 52 kD SSA/Ro and autoimmune-associated congenital heart block. J Autoimmunity 19: 79–86

    Article  Google Scholar 

  22. Kamel R et al. (2005) Autoantibodies against the serotoninergic 5-HT4 receptor and congenital heart block: a reassessment. J Autoimmun 25: 72–76

    Article  CAS  PubMed  Google Scholar 

  23. Clancy RM et al. (2004) Immunohistologic evidence supports apoptosis, IgG deposition and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum 50: 173–182

    Article  CAS  PubMed  Google Scholar 

  24. Clancy RM et al. (2006) Impaired clearance of apoptotic cardiocytes linked to anti-SSA/Ro-SSB/La antibodies in pathogenesis of congenital heart block. J Clin Investigation 116: 2413–2422

    CAS  Google Scholar 

  25. Clancy RM et al. (2002) Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block. J Immunol 169: 2156–2163

    Article  CAS  PubMed  Google Scholar 

  26. Miranda-Carús ME et al. (2000) Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of tumor necrosis factor α by macrophages. J Immunol 165: 5345–5351

    Article  PubMed  Google Scholar 

  27. Clancy RM et al. (2003) Cytokine polymorphisms and histologic expression in autopsy studies: contribution of TNF-α and TGFβ1 to the pathogenesis of autoimmune-associated congenital heart block. J Immunol 171: 3253–3261

    Article  CAS  PubMed  Google Scholar 

  28. Clancy RM et al. (2007) Role of hypoxia and cAMP in the transdifferentiation of human fetal cardiac fibroblasts: implications for progression to scarring in autoimmune-associated congenital heart block. Arthritis Rheum 56: 4120–4131

    Article  CAS  PubMed  Google Scholar 

  29. McCue CM et al. (1977) Congenital heart block in newborns of mothers with connective tissue disease. Circulation 56: 82–90

    Article  CAS  PubMed  Google Scholar 

  30. Geggel RL et al. (1988) Postnatal progression from second- to third-degree heart block in neonatal lupus syndrome. J Ped 113: 1049–1052

    Article  CAS  Google Scholar 

  31. Askanase AD et al. (2002) Spectrum and progression of conduction abnormalities in infants born to mothers with anti-Ro/La antibodies. Lupus 11: 145–151

    Article  CAS  PubMed  Google Scholar 

  32. Saleeb S et al. (1999) Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block. Arthritis Rheum 42: 2335–2345

    Article  CAS  PubMed  Google Scholar 

  33. Jaeggi ET et al. (2004) Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 110: 1542–1548

    Article  PubMed  Google Scholar 

  34. Rosenthal D et al. (1998) A new therapeutic approach to the fetus with congenital complete heart block: pre-emptive, targeted therapy with dexamethasone. Obstet Gynecol 92: 689–691

    Article  CAS  Google Scholar 

  35. Breur JMPJ et al. (2004) Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature. Ultrasound Obstet Gynecol 24: 467–472

    Article  CAS  PubMed  Google Scholar 

  36. Brucato A et al. (2006) Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero. Ann Rheum Dis 65: 1422–1426

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Airo' P et al. (2006) Characterization of T-cell population in children with prolonged fetal exposure to dexamethasone for anti-Ro/SS-A antibodies associated congenital heart block. Lupus 15: 553–561

    Article  CAS  PubMed  Google Scholar 

  38. Sonesson SE et al. (2004) Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52 kD antibodies. Arthritis Rheum 50: 1253–1261

    Article  CAS  PubMed  Google Scholar 

  39. Andelfinger G et al. (2001) Reference values for time intervals between atrial and ventricular contractions of the fetal heart measured by two Doppler techniques. Am J Cardiol 88: 1433–1436

    Article  CAS  PubMed  Google Scholar 

  40. Clancy RM et al. (2002) Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block. J Immunol 169: 2156–2163

    Article  CAS  PubMed  Google Scholar 

  41. Kaaja R and Julkunen H (2003) Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al. [letter]. Arthritis Rheum 48: 281–282

    Article  Google Scholar 

  42. Looney RJ and Huggins J (2006) Use of intravenous immunoglobulin (IVIG). Best Pract Res Clin Haematol 18: 3–25

    Article  Google Scholar 

  43. Samuelsson A et al. (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 445–446

    Article  Google Scholar 

  44. Nimmerjahn F and Ravetch JV (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26: 513–533

    Article  CAS  PubMed  Google Scholar 

  45. Anthony RM et al. (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320: 373–376

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Preventive IVIG Therapy for Congenital Heart Block (PITCH) [http://clinicaltrials.gov/ct2/show/NCT00460928?term=NCT00460928&rank=1] (accessed 13 January 2009)

Download references

Acknowledgements

This work was funded by an NIH-NIAMS grant (Maternal Autoantibodies: Pathogenesis of Neonatal Lupus), an NIH contract (Research Registry for Neonatal Lupus) and an NIH-NIAMS grant (the PRIDE study) to Dr Buyon, and an American Heart Association, Heritage Affiliate grant to Dr Clancy.

Author information

Authors and Affiliations

  1. JP Buyon is Professor and Associate Director of the Division of Rheumatology, New York Medical College, New York, NY, USA.,

    Jill P Buyon

  2. RM Clancy is Associate Professor at the New York University School of Medicine, New York, NY, USA.,

    Robert M Clancy

  3. DM Friedman is Professor of Pediatric Cardiology at the New York Medical College, New York, NY, USA.,

    Deborah M Friedman

Authors
  1. Jill P Buyon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert M Clancy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deborah M Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jill P Buyon.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buyon, J., Clancy, R. & Friedman, D. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Rev Rheumatol 5, 139–148 (2009). https://doi.org/10.1038/ncprheum1018

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum1018

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing